


Idis Pharma Limited

Annual Report and Unaudited Financial Statements

For the year ended 30 June 2022

Company Number: 09964075

FRIDAY



ACØHCGCR

A21

31/03/2023

#194

COMPANIES HOUSE

Idis Pharma Limited

Balance sheet at 30 June 2022

Company number 09964075	Note	2022 £	2021 £
Current assets			
Debtors	3	1	1
Net assets		1	1
Capital and reserves			
Called up share capital	4	1	1
Total shareholders' funds		1	1

Idis Pharma Limited (the "Company") did not trade during either of the financial years under review and so no profit and loss account or statement of changes in total equity have been prepared. The Company has not received any income, incurred any expense or recognised any other gains or losses.

For the year ended 30 June 2022, the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies. The members have not required the Company to obtain an audit of its financial statements for the year ended 30 June 2022 in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements on pages 1 and 2 were approved by the board and authorised for issue on 31 March 2023.



RJ Paling
Director
On behalf of the board

Idis Pharma Limited

Notes to the financial statements for the year ended 30 June 2022

1 Accounting policies

Basis of preparation of financial statements

These financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006 and UK Generally Accepted Accounting Practice (GAAP).

Reporting currency

These financial statements are presented in sterling, the Company's functional currency.

2 Profit and loss account and statement of comprehensive income

The Company did not trade during the current or prior year and accordingly no profit and loss account is presented. It had no other income or charges in either the current or prior year and accordingly no statement of comprehensive income is presented.

The Company had no employees during the current or prior year and accordingly no employee costs are included in these financial statements (2021: £nil). No directors received any remuneration in respect of their services to the Company (2021: £nil).

3 Debtors

	2022 £	2021 £
Amounts owed by group undertakings	1	1

The amounts owed by group undertakings are non-interest bearing and receivable on demand.

4 Called up share capital

	2022 £	2021 £
Issued, allotted, called up and fully paid 1 ordinary share of £1 each	1	1

5 Ultimate parent undertaking and controlling party

The Company's ultimate parent undertaking and ultimate controlling party is Triton Fund V which is managed and controlled by its general partners Triton Managers V Limited and TTF V Limited.

Clinigen Limited, a company incorporated and registered in the UK, is the parent of the smallest group of undertakings to consolidate these financial statements and Triley Holdco Limited, a company incorporated and registered in Jersey, is the parent of the largest group of undertakings to consolidate these financial statements. The registered addresses respectively are Clinigen Limited, Pitcairn House, Crown Square, Centrum 100, Burton-on-Trent, Staffordshire, DE14 2WW and Triley Holdco Limited, c/o Triton, 1st Floor, 5/6 Esplanade, St Helier, Jersey, JE2 3QA.